Axsome Plans 600-Rep Field Force as Auvelity Scripts Surge, ADA PDUFA April 30
At an investor conference on Feb. 26, Axsome Therapeutics reported robust Auvelity scripts momentum and outlined a plan to deploy a 600-representative sales force by mid-year. Its ADHD candidate ADA now has an FDA action date set for April 30, marking a pivotal regulatory milestone.
1. Conference Presentation Highlights
At the Feb. 26 Oppenheimer conference, Axsome’s leadership detailed accelerating uptake of its newly launched Auvelity treatment for major depressive disorder, underscoring sequential growth in weekly prescription volumes since launch.
2. Sales Force Expansion Plan
Axsome plans to scale its commercial team to 600 field representatives by mid-2026, aiming to broaden prescriber access and drive further momentum across its Auvelity rollout.
3. ADA Regulatory Milestone
The company confirmed an FDA action date of April 30 for its ADHD candidate ADA, positioning this decision as a critical catalyst for potential label expansion and revenue diversification.